Tech Company Financing Transactions
Innocrin Funding Round
Innocrin secured a $28 million Series D financing round on 4/16/2015. Backers included Eshelman Ventures, Hatteras Venture Partners and Intersouth Partners.
Transaction Overview
Company Name
Announced On
4/16/2015
Transaction Type
Venture Equity
Amount
$28,000,000
Round
Series D
Investors
Eshelman Ventures (Lead Investor) (Fred Eshelman)
Proceeds Purpose
Innocrin plans to use the proceeds to accelerate parallel Phase 2 CRPC program studies that are being led by the Memorial Sloan Kettering Cancer Center (MSK) and the NCI.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4505 Emperor Blvd. 315
Durham, NC 27703
USA
Durham, NC 27703
USA
Phone
Website
Email Address
Not Recorded
Overview
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Fred Eshelman
Chief Financial Officer
Charles Osborne
Chief Medical Officer
Edwina Baskin-Bey
Browse more venture capital transactions:
Prev: 4/16/2015: 99designs venture capital transaction
Next: 4/16/2015: Procore Technologies venture capital transaction
Share this article
About Database of VC Transactions
We document all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs